On Oct 31, major Wall Street analysts update their ratings for $Blueprint Medicines (BPMC.US)$, with price targets ranging from $105 to $155.
Morgan Stanley analyst Michael Ulz maintains with a hold rating, and maintains the target price at $120.
Barclays analyst Peter Lawson maintains with a hold rating, and maintains the target price at $105.
Wells Fargo analyst Derek Archila maintains with a buy rating, and adjusts the target price from $153 to $151.
TD Cowen analyst Marc Frahm maintains with a buy rating.
Oppenheimer analyst Matthew Biegler maintains with a buy rating, and maintains the target price at $130.
Furthermore, according to the comprehensive report, the opinions of $Blueprint Medicines (BPMC.US)$'s main analysts recently are as follows:
The firm maintains a bullish stance on the shares, anticipating that the guidance for Ayvakit for FY25 will surpass consensus predictions. Additionally, the potential positive data from the early-stage trial of POS BLU-808 in early 2025 is expected to provide further upside.
Here are the latest investment ratings and price targets for $Blueprint Medicines (BPMC.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$Blueprint Medicines (BPMC.US)$的評級，目標價介於105美元至155美元。
摩根士丹利分析師Michael Ulz維持持有評級，維持目標價120美元。
巴克萊銀行分析師Peter Lawson維持持有評級，維持目標價105美元。
富國集團分析師Derek Archila維持買入評級，並將目標價從153美元下調至151美元。
TD Cowen分析師Marc Frahm維持買入評級。
奧本海默控股分析師Matthew Biegler維持買入評級，維持目標價130美元。
此外，綜合報道，$Blueprint Medicines (BPMC.US)$近期主要分析師觀點如下：
以下爲今日9位分析師對$Blueprint Medicines (BPMC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
